

Optimer Pharmaceuticals

[View the current Optimer Pharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/bioporfolio/27625-Optimer+Pharmaceuticals.html)

(<http://www.bioportfolio.com/bioporfolio/27625-Optimer+Pharmaceuticals.html>)

Contact Details:

**10110 Sorrento Valley Rd, Suite C
San Diego
California
92121
United States of America**

Tel: (858) 909-0736

Fax: 858.909.0737

Email: info@optimerpharma.com

Optimer's core competence includes the development of innovative drugs for treating diseases that currently have no satisfactory therapy. These include antibiotics for drug-resistant bacterial infections, a cancer vaccine, and "disease-modifying" drugs for osteoarthritis. In the near term Optimer plans to bring in significant revenues through sponsored research, joint ventures, government grants, and license royalties. Optimer Pharmaceuticals, Inc. was founded and registered as a Delaware Corporation in 1998. The Company has licensed its technologies and therapeutic targets from The Scripps Research Institute and The Memorial Sloan-Kettering Cancer Center. These licenses form the core of Optimer's carbohydrate technologies. Under the leadership of its three founding scientists Michael Chang, Ph.D. (Optimer Pharmaceutical's President and CEO), Professor Chi-Huey Wong of Scripps Research Institute and Professor Samuel Danishefsky of Memorial Sloan-Kettering Cancer Center, the company has already assembled one of the best research and development teams in the field of carbohydrate technology. The Company headquarters and R&D laboratory are located in San Diego, California, less than ten minutes away from The Scripps Research Institute. Optimer also has two wholly owned subsidiary, Optimer Singapore Pte Ltd., located in Singapore, and Optimer Taiwan, located in Taipei, Taiwan

Recent Publications by Optimer Pharmaceuticals:



- [Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.](#)
Current therapies for Clostridium difficile infection (CDI) are encumbered... 4th July, 2008
Optimer Pharmaceuticals, Inc., 10110 Sorrento Valley Road, San Diego, CA- Antimicrob Agents Chemother. 2008 Apr;52(4):1391-5. Epub 2008 Feb 11. ([DOI Direct Link](#))
- [Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities.](#)

A library of 4,5- and 4,6-linked bivalent aminoglycoside (AMG) antibiotics... 19th August, 2005
 Department of Chemistry, Optimer Pharmaceuticals, Inc., 10110 Sorrento- Bioorg Med Chem Lett.
 2005 Apr 15;15(8):2123-8. ([DOI Direct Link](#))

- [Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics.](#)
A series of new triazole-containing ketolides and 2-fluoro-ketolides in... 6th July, 2005
 Department of Chemistry, Optimer Pharmaceuticals, Inc., 10110 Sorrento- Bioorg Med Chem Lett.
 2005 Mar 1;15(5):1307-10. ([DOI Direct Link](#))
- [Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agents.](#)
Glyco-optimization (OPopS) of aminoglycosides has been performed by... 8th February, 2005
 Department of Chemistry, Optimer Pharmaceuticals, Inc., 10110 Sorrento- Bioorg Med Chem Lett.
 2004 Jul 16;14(14):3733-8. ([DOI Direct Link](#))

Press Releases on Optimer Pharmaceuticals:

Reportlinker Adds Imaging Agents - A Worldwide Market Review	20th November, 2009	Reportlinker	<i>NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Imaging Agents - A Worldwide Market Review http://www.reportlinker.com</i>
------------------------------------------------------------------------------	---------------------	--------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AstraZeneca and the Philadelphia Department of Public Health Provide Free Medicines to Pennsylvania's Uninsured	20th November, 2009	AstraZeneca	<i>WILMINGTON, Del., Nov. 20 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and the Philadelphia Department of Public Health announced today at a press conference at Philadelphia Health Care Center #6</i>
---------------------------------------------------------------------------------------------------------------------------------	---------------------	-------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Impax Laboratories Drives Stronger Performance with IBM Business Analytics	20th November, 2009	IBM	<i>-- C-level Executive Committee can now easily pull together a single view of net sales, profitability and competitive market share information, helping them to determine whether</i>
--------------------------------------------------------------------------------------------	---------------------	-----	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference	19th November, 2009	Alexza Pharmaceuticals, Inc.	<i>MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that its corporate presentation will be webcast live during the 21st Annual Piper</i>
-----------------------------------------------------------------------------------------------------------	---------------------	------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season](#)

19th November, 2009 Medialink

NEW YORK, Nov. 19 /PRNewswire/ -- As the seasons change, another season of coughs and running noses is here. Here's more on preparing yourself. Listen to this report from Ortho-McNeil-Janssen

BioNews Results for Optimer Pharmaceuticals



- [Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clo](#)
Genetic Engineering News: Nov 14 2009 5:18PM Matching: optimer pharmaceuticals
- [Optimer Pharmaceuticals Completes Enrollment In Second Fidaxomicin Phase 3 Clinical Trial In Patients With Clostridium Difficile Infection](#)
Medical News Today: Nov 13 2009 4:49PM Matching: optimer pharmaceuticals
- [Medical News: Optimer Pharmaceuticals Completes Enrollment In Second Fidaxomicin Phase 3 Clinical Trial In Patients With Clostridium Difficile Infection](#)
BioFind: Nov 13 2009 1:16PM Matching: optimer pharmaceuticals
- [Optimer completes enrollment in second Phase III study of fidaxomicin for treatment of Clostridium difficile i](#)
Pharmacy Choice: Nov 13 2009 2:29AM Matching: optimer pharmaceuticals
- [Oppenheimer Upgrades Optimer Pharmaceuticals \(OPTR\) to Outperform](#)
Street Insider: Nov 12 2009 8:27PM Matching: optimer pharmaceuticals
- [Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clostridium difficile Infection](#)
Individual.com: Nov 12 2009 6:47PM Matching: optimer pharmaceuticals
- [Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clo](#)
Pharmacy Choice: Nov 12 2009 10:11PM Matching: optimer pharmaceuticals
- [Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clo](#)
KSLA: Nov 12 2009 6:17PM Matching: optimer pharmaceuticals
- [Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clostridium difficile Infection](#)
Yahoo! Canada: Nov 12 2009 4:26PM Matching: optimer pharmaceuticals
- [Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clo](#)
Therapeutics Daily: Nov 12 2009 2:49PM Matching: optimer pharmaceuticals
- [Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clo](#)
Montana's News Station: Nov 12 2009 2:16PM Matching: optimer pharmaceuticals
- [Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clo](#)
Pharma Live: Nov 12 2009 2:12PM Matching: optimer pharmaceuticals
- [Optimer Pharma's Enrollment Announcement Brings Some Relief](#)
Wall Street Journal Online: Nov 12 2009 7:03PM Matching: optimer pharmaceuticals

- [Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clo](#)

PR Newswire via Yahoo!: Nov 12 2009 1:09PM Matching: optimer pharmaceuticals

- [Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results](#)

PR Newswire: Nov 8 2009 5:56PM Matching: optimer pharmaceuticals

Optimer Pharmaceuticals Patents:



- 7601695- [Antibacterial agents](#)
- 7507564- [Tiacumicin production](#)
- 7414885- [Method and apparatus for reading data from a ferromagnetic memory cell](#)
- 7378508- [Polymorphic crystalline forms of tiacumicin B](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

